Holen Sie sich die Stockscreener-App
1.0251
2.38%
-0.0249
Schlusskurs vom Vortag:
$1.05
Offen:
$1.07
24-Stunden-Volumen:
92,132
Relative Volume:
0.11
Marktkapitalisierung:
$66.98M
Einnahmen:
$9.14M
Nettoeinkommen (Verlust:
$-124.31M
KGV:
-1.0708
EPS:
-0.9573
Netto-Cashflow:
$-125.43M
1W Leistung:
+4.58%
1M Leistung:
+4.39%
6M Leistung:
-13.14%
1J Leistung:
-29.31%
1-Tages-Spanne:
$1.01
$1.07
1-Wochen-Bereich:
$0.98
$1.12
52-Wochen-Spanne:
$0.8251
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.025 | 69.27M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
520.41 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.00 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.27 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.90 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace By Investing.com - Investing.com Canada
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace - Investing.com
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
TScan Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRX) - TradingView
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com South Africa
TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00 - GuruFocus
TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Sahm
TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com
Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks
TScan reports trial data for blood cancer treatment TSC-101 - Investing.com
TScan reports trial data for blood cancer treatment TSC-101 By Investing.com - Investing.com Australia
TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire
TCRX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Advances Without RevenueFinancial Summary - newsline.com
TScan Therapeutics Cuts Net Loss to 28 Million Dollars - asatunews.co.id
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Insider Monkey
TScan Therapeutics hangs around $1.08; eyes on next week - Bez Kabli
TScan Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Growth Report - The Legal Advocate
TCRXTscan Therapeutics Inc Stock Price and Quote - Finviz
TScan Therapeutics (TCRX) Rallies 3.9% as Shares Test Key Resistance LevelsPercent Below MA - The Legal Advocate
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressConsensus Forecast Report - The Legal Advocate
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - The Globe and Mail
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX - Benzinga
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.82%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):